This study focuses on young people aged 12 to 17 who have chronic migraine, a condition where headaches occur frequently and significantly impact daily life. The research evaluates a medication called eptinezumab (also known as VYEPTI), which is given through intravenous administration (directly into a vein). The purpose is to determine if this treatment can reduce the number of days that young patients experience migraines compared to those receiving a placebo.
The study medication or placebo will be given as an infusion solution that is administered into a vein. The treatment period lasts for 12 weeks, during which participants will receive the study medication or placebo. The study uses a method called “double-blind,” which means neither the participants nor the doctors know who receives which treatment during the study.
Throughout the study, participants will need to keep track of their migraine days using an electronic diary. The researchers will monitor how the treatment affects migraine frequency and will also check for any changes in how often patients need to use other migraine medications. They will also evaluate how the treatment impacts the participants’ daily activities and overall quality of life.
Italy 
Poland 
Portugal 
Spain 
